These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28058373)

  • 1. Pustular eruption induced by etanercept in a patient with ankylosing spondylitis: a rare side effect.
    Kara A; Alatas ET; Celebi HS; Dogan G; Dere Y
    North Clin Istanb; 2015; 2(3):231-235. PubMed ID: 28058373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis.
    Park JJ; Lee SC
    Ann Dermatol; 2010 May; 22(2):212-5. PubMed ID: 20548918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept: in ankylosing spondylitis.
    McCormack PL; Wellington K
    BioDrugs; 2004; 18(3):199-205; discussion 206. PubMed ID: 15161337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.
    Tolu S; Rezvani A; Hindioglu N; Calkin Korkmaz M
    Rheumatol Int; 2018 Nov; 38(11):2157-2162. PubMed ID: 30293157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
    Wiedmann MW; Mössner J; Baerwald C; Pierer M
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
    Fleischmann R; Iqbal I
    Drugs Aging; 2007; 24(3):239-54. PubMed ID: 17362051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature.
    Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S
    Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of etanercept in the dermatology setting. A review.
    Lebwohl MG
    Am J Clin Dermatol; 2005; 6(1):49-59. PubMed ID: 15675890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.
    Cobo-Ibáñez T; Martín-Mola E
    Expert Opin Pharmacother; 2007 Jun; 8(9):1373-97. PubMed ID: 17563271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Etanercept].
    Sparsa A
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):861-76. PubMed ID: 16327716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V; Mergler S; Pleyer U
    Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
    Zhou H
    J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.